answer text |
<p>The Medicines and Healthcare products Regulatory Agency (MHRA) is the Government
body responsible for the safety and licensing of medicines in the United Kingdom.</p><p>
</p><p> </p><p> </p><p>Under their terms of service, general practitioners and hospital
doctors are allowed to prescribe any medicinal product, including any unlicensed medicinal
product, in order to meet special clinical need (subject to any local funding arrangements).
They should always satisfy themselves that the medicinal products, or other substances
they consider appropriate for their patients, can be safely prescribed, that patients
are adequately monitored and that, where necessary, expert hospital supervision is
available.</p><p> </p><p> </p><p> </p><p>The administration of medicinal products
to patients undergoing fertility treatment is a matter of clinical judgment by the
treating clinician. It is not regulated by the Human Fertilisation and Embryology
Authority (HFEA). The National Institute for Health and Care Excellence’s Guideline
<em>Fertility, Assessment and treatment for people with fertility</em> problems provides
guidance for healthcare professionals on the use of such products, including those
used for ovarian stimulation. The HFEA has advised that it does not collect information
on the identity of medicinal products used in treatment.</p><p> </p><p> </p><p> </p><p>The
HFEA is aware of some clinics that have administered reagents to permitted gametes
or permitted embryos that are then introduced into patients when the reagents concerned
have not been CE marked. Such instances are identified by sample audits conducted
during the course of inspection and documented in the report of the inspection.</p><p>
</p><p> </p><p> </p><p>Although the HFEA does not hold information on the effects
of particular dosages on the welfare of the developing child and the health of the
mother, the HFEA expects clinics to do such monitoring as part of their licensing
conditions.</p><p> </p>
|
|